HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company that specializes in developing immunotherapeutics to treat infectious diseases and cancers. The company's lead products for infectious diseases are HB-101, which is in Phase II clinical trial, and HB-201 and HB-202, which are in Phase I/II clinical trials for treating HPV16-positive cancers. The company also has preclinical stage products, including the HB-300 program for prostate cancer and HB-700 program for targeting mutated KRAS.